Intelligent Bio Solutions Inc. (INBS)
USD 1.29
(4.88%)
USD 1.29
(4.88%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 3.11 Million USD | 147.58% |
| 2023 | 1.25 Million USD | 0.0% |
| 2022 | - USD | -100.0% |
| 2021 | 1.98 Million USD | 949.3% |
| 2020 | 188.74 Thousand USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 FY | 3.11 Million USD | 147.58% |
| 2024 Q1 | 796.09 Thousand USD | 79.65% |
| 2024 Q2 | 764.06 Thousand USD | -4.02% |
| 2024 Q3 | 823.8 Thousand USD | 7.82% |
| 2024 Q4 | 727.82 Thousand USD | -11.65% |
| 2023 Q4 | 443.13 Thousand USD | -3.05% |
| 2023 FY | 1.25 Million USD | 0.0% |
| 2023 Q3 | 457.05 Thousand USD | 28.14% |
| 2023 Q2 | 356.67 Thousand USD | 14.57% |
| 2023 Q1 | 311.32 Thousand USD | 0.0% |
| 2022 Q2 | - USD | 0.0% |
| 2022 Q4 | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 FY | - USD | -100.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 FY | 1.98 Million USD | 949.3% |
| 2021 Q3 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | 188.74 Thousand USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 90.042% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | 76.721% |
| Aspira Women's Health Inc. | 9.15 Million USD | 66.006% |
| Biodesix, Inc. | 49.08 Million USD | 93.661% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | 68.152% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -22.874% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -22.874% |
| Bionano Genomics, Inc. | 36.11 Million USD | 91.384% |
| CareDx, Inc | 280.32 Million USD | 98.89% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 219.78 Million USD | 98.584% |
| DarioHealth Corp. | 20.35 Million USD | 84.71% |
| Exact Sciences Corporation | 2.49 Billion USD | 99.876% |
| Fulgent Genetics, Inc. | 289.21 Million USD | 98.924% |
| Guardant Health, Inc. | 563.94 Million USD | 99.448% |
| ICON Public Limited Company | 8.12 Billion USD | 99.962% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 99.915% |
| Illumina, Inc. | 4.5 Billion USD | 99.931% |
| iSpecimen Inc. | 9.92 Million USD | 68.657% |
| Standard BioTools Inc. | 106.34 Million USD | 97.074% |
| MDxHealth SA | 70.19 Million USD | 95.567% |
| 23andMe Holding Co. | 219.63 Million USD | 98.583% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 99.835% |
| Myriad Genetics, Inc. | 678.4 Million USD | 99.541% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -247.499% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| NeoGenomics, Inc. | 591.64 Million USD | 99.474% |
| Neogen Corporation | 924.22 Million USD | 99.663% |
| Inotiv, Inc. | 572.42 Million USD | 99.456% |
| Natera, Inc. | 1.08 Billion USD | 99.713% |
| OpGen, Inc. | 3.41 Million USD | 8.968% |
| OPKO Health, Inc. | 863.49 Million USD | 99.64% |
| Psychemedics Corporation | 22.09 Million USD | 85.918% |
| Prenetics Global Limited | 21.74 Million USD | 85.688% |
| Prenetics Global Limited | 21.74 Million USD | 85.688% |
| Precipio, Inc. | 15.19 Million USD | 79.524% |
| Personalis, Inc. | 73.48 Million USD | 95.765% |
| RadNet, Inc. | 1.61 Billion USD | 99.808% |
| Sera Prognostics, Inc. | 306 Thousand USD | -916.922% |
| Sotera Health Company | 1.04 Billion USD | 99.703% |
| Neuronetics, Inc. | 71.34 Million USD | 95.639% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 93.203% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 93.203% |
| Trinity Biotech plc | 56.83 Million USD | 94.525% |
| T2 Biosystems, Inc. | 7.19 Million USD | 56.739% |
| Twist Bioscience Corporation | 312.97 Million USD | 99.006% |
| Exagen Inc. | 52.54 Million USD | 94.078% |